Federated Hermes Inc. Sells 875,010 Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)

Key Points

• Federated Hermes Inc. sold 875,010 shares of Structure Therapeutics, reducing its holdings by 42.8% to approximately 1.17 million shares, valued at $20.27 million.
• Structure Therapeutics has a market capitalization of $1.02 billion and reported a quarterly loss of ($0.27) EPS, missing analysts' expectations.
• Analysts currently have a consensus "Buy" rating for Structure Therapeutics, with an average price target of $76.17, while various firms set individual target prices ranging from $60.00 to $89.00.

Federated Hermes Inc. cut its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 42.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,170,948 shares of the company's stock after selling 875,010 shares during the period. Federated Hermes Inc. owned approximately 2.04% of Structure Therapeutics worth $20,269,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the business. GF Fund Management CO. LTD. acquired a new stake in shares of Structure Therapeutics in the 4th quarter valued at about $34,000. Virtus ETF Advisers LLC grew its stake in shares of Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company's stock valued at $61,000 after buying an additional 455 shares during the period. ANTIPODES PARTNERS Ltd grew its stake in shares of Structure Therapeutics by 310.7% in the 1st quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock valued at $74,000 after buying an additional 3,213 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of Structure Therapeutics by 673.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,076 shares of the company's stock valued at $111,000 after buying an additional 3,549 shares during the period. Finally, Headlands Technologies LLC acquired a new stake in shares of Structure Therapeutics in the 4th quarter valued at about $113,000. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Stock Performance

GPCR stock opened at $17.80 on Friday. The company has a market capitalization of $1.02 billion, a P/E ratio of -20.46 and a beta of -1.87. Structure Therapeutics Inc. Sponsored ADR has a 52-week low of $13.22 and a 52-week high of $45.37. The business has a 50-day simple moving average of $20.57 and a two-hundred day simple moving average of $22.27.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). As a group, sell-side analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently commented on GPCR shares. Citigroup started coverage on Structure Therapeutics in a research note on Friday, May 2nd. They issued a "buy" rating and a $60.00 target price for the company. HC Wainwright reduced their target price on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a research note on Monday, May 12th. Cantor Fitzgerald reiterated an "overweight" rating and set a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, June 23rd. Finally, JMP Securities reiterated a "market outperform" rating and set a $89.00 price target on shares of Structure Therapeutics in a research note on Monday, June 23rd. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics currently has a consensus rating of "Buy" and an average price target of $76.17.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.